Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib (IMAGE)
Caption
Figure 3: CNS disease response on amivantamab. MRI Brain at the time of pre-treatment (A(i–iv)), 6 months (B(i–iv)), 19 months (C(i–iv)) post-treatment demonstrating complete resolution of CNS disease at 6 months (B(i–iv)), and 19 months (C(i–iv)).
Credit
Copyright: © 2025 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content